NorthSea Therapeutics completes US$80m Series C financing
Dutch metabolic disease specialist NorthSea Therapeutics NV has baged US$80m in a Series C fundraising co-led by Ysios Capital and Forbion Growth.
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1247 entries already.
Entries by Thomas Gabrielczyk
Depixus raises 30.6m in Series A financing
/in News/by Thomas GabrielczykFrench-British magnetic trap specialist Depixus has raised 30,6m to develop a commercial instrument based on the companys MAGNA technology.
Ichnos Sciences in licence deal with Almirall
/in News/by Thomas GabrielczykIchnos Sciences Inc. has licenced the gobal rights on its IL-1RAP antagonistic antibody ISB 880 to Almirall SA for the treatment of autoimmune disorders.
Vifor Pharma Ltd to be acquired for CHF10.9bn
/in News/by Thomas GabrielczykBiologicals and vaccine specialist CSL Ltd is set to acquire Swiss Vifor Pharma Ltd for CHF10.9bn.
Apogenix gets 25.8m cash injection for asunercept
/in News/by Thomas GabrielczykGerman Apogenix AG has received a 26m in funding for a pivotal Phase III study of its CD95 ligand blocker asunercept for the treatment of COVID-19 patients.
British Adendra Therapeutics closes $53m financing
/in News/by Thomas GabrielczykThe 2021 spin out of London-based Francis Crick Institute is the very first UK company formation deal of life sciences investor ATP (Apple Tree Partners).
US-Greek Venture gets 32m cash injection
/in News/by Thomas GabrielczykUS cell & gene therapy manufacturer Orgenesis Inc. announced that its joint venture with Theracell Advanced Biotechnology SA has received 32m in funding by Enterprise Greece.
EC signs prepurchase agreement with Valneva
/in News/by Thomas GabrielczykThe European Commission has inked the pre-purchase agreement over Valnevas inactivated whole virus pandemic vaccine VLA2001 announed in mid-October.
Novo Nordisk snatches Dicerna
/in News/by Thomas GabrielczykNovo Nordisk announced today that it has entered into a definitive agreement to acquire Dicerna Pharmaceuticals for up to US$ 3.3bn, which is a surcharge of about 80%.
LSP and EQT merge to create top-10 investment firm
/in News/by Thomas GabrielczykLife Sciences investor LSP is set to being acquired by Europe’s largest equity specialist EQT AB.